Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

More on the new study.

Compete for the Flemingsberg Science Award STARTUP 2024– take your ideas to the next level

Finally, registration for the Flemingsberg Science Award STARTUP 2024 is open. Do you have an exciting business idea that deserves expert testing? Are you ready to take it to the next level? Then this competition is perfect for you. Participate and compete for a prize of 10,000 SEK and three months of membership at Innovation Station - a coworking space, innovation hub, and meeting place in the heart of Campus Flemingsberg. 

2023-06-22T12:22:38+02:00
Go to Top